Isoquercetin

Phase 2Small molecule

JJeffrey Zwicker, MD

Isoquercetin is one of 49 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerRecruiting

Platelet FunctionWithdrawn

Ovarian CancerPhase 2

Recruiting

Platelet FunctionPreclinical

Withdrawn

Competition

Competitive Landscape

209 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

33 2

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

24 5

Femara

Novartis

Phase 3

8 6

Imfinzi

AstraZeneca

Phase 3

8 7

Opdivo

Bristol-Myers Squibb

Phase 3

8 8

Adriamycin

Pfizer

Phase 3

8 9

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Neulasta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Ovarian Cancer

NCT07303894

Clinical

Trials by Indication[1]

COVID-193 trials

Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Unknown status·AAB Science·Phase 2·NCT04622865·200 enrolled

Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

Withdrawn·IInstitut de Recherches Cliniques de Montreal·Phase 2·NCT04536090

Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19

Unknown status·NNepal Health Research Council·Phase 2·NCT04733651·250 enrolled

Kidney Cancer1 trial

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

Unknown status·CConsorzio Oncotech·Phase 1/2·NCT02446795·104 enrolled

Sickle Cell Disease1 trial

Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT04514510·46 enrolled

Thrombosis1 trial

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

Completed·JJeffrey Zwicker, MD·Phase 2/3·NCT02195232·64 enrolled

Platelet Function1 trial

Impact of isoQUercetin and Aspirin on Platelet Function

Withdrawn·UUniversity of Reading·N/A·NCT02866448

2 more indications

Anemia1 trial

Isoquercetin in Sickle Cell Anemia

Withdrawn·JJeffrey Zwicker, MD·Phase 2·NCT04474626

Ovarian Cancer1 trial

Randomized, Multi-dose, Placebo-controlled Phase 2 Trial of Oral Isoquercetin to Reduce Thrombin Generation in Ovarian Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07303894·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Isoquercetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isoquercetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isoquercetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jeffrey Zwicker, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJeffrey Zwicker, MD

Isoquercetin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

COVID-193 trials

Kidney Cancer1 trial

Sickle Cell Disease1 trial

Thrombosis1 trial

Platelet Function1 trial

Anemia1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News